Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation

V Martinelli, G Dalla Costa, Francesca Sangalli, B Colombo, M Robotti, L Moiola, G Comi

Research output: Contribution to journalArticle

Abstract

Daclizumab, a MS treatment targeting IL2-receptor, has been recently withdrawn following reports of immune-mediated encephalitis. We report the case of a 39-years-old woman treated with daclizumab that presented a progressive decrease in the strength at her lower limbs which further worsened after the drug was stopped. Post-treatment MRI showed more than 20 new enhancing lesions. No symptoms nor signs associated with immune-mediated encephalitis were present. Our case highlights the problem of disease course after daclizumab discontinuation and urge neurologists to strictly monitor patients discontinuing the drug in order to exclude both the occurrence of immune-mediated encephalitis and disease reactivation. Copyright © 2018. Published by Elsevier B.V.
Original languageEnglish
Pages (from-to)57-59
Number of pages3
JournalMultiple Sclerosis and Related Disorders
Volume28
DOIs
Publication statusPublished - 2018

Fingerprint Dive into the research topics of 'Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation'. Together they form a unique fingerprint.

  • Cite this